(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. Docetaxel was the first agent to demonstrate a survival benefit in metastatic castration resistant prostate cancer (mCRPC) and has subsequently demonstrated benefit in metastatic castration-sensitive disease. However, the optimal use of docetaxel is not clear and it may be underutilized. Thus, biomarkers and prediction models assessing efficacy and toxicity of docetaxel may help optimize treatment selection.